Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 36 Gynecologic 19 Genitourinary 19 Tumor-Agnostic 11 Other solid neoplasm 11 Gastrointestinal 10 Thoracic 9 Other hematologic neoplasm 7 CNS 4 Sarcoma 3 Myeloid 2 Lymphoid 2 Head & Neck 2 Endocrine 2 Plasma cell 1 NET 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 41 Everolimus 38 Magnetic Resonance Spectroscopy 18 Temozolomide 17 lanreotide 16 gallium Ga 68 dotatate 15 Octreotide 14 pembrolizumab 13 Nivolumab 13 Capecitabine 12 cabozantinib 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 surufatinib 9 pasireotide 9 Sunitinib 9 Specimen Handling 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 Lutetium-177 8 Carboplatin 8 amino-acid, glucose, and electrolyte solution 6 Ipilimumab 6 Ga(III)-DOTATOC 6 Fluorodeoxyglucose F18 6 Etoposide 6 Cisplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 copper dotatate CU-64 5 Injections 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × talazoparib × NET × Clear all

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡